PRLD
Prelude Therapeutics Inc
Key Financials
EPS (Diluted)
$-1.29
↑ 23.2%
Total Assets
$141.3M
↓ 19.5%
Net Income
$-99498000
↑ 21.8%
Shareholders' Equity
$68.6M
↓ 47.8%
Cash & Equivalents
$35.3M
↑ 182.6%
Total Liabilities
$72.7M
↑ 65.0%
Operating Cash Flow
$-56302000.00
↑ 45.3%
Revenue
$12.1M
↑ 73.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/10/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| SCHEDULE 13G | 7/8/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PRLD |
| Company Name | Prelude Therapeutics Inc |
| CIK | 1678660 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (302) 467-1280 |